-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-22-2026 TO 02-28-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$ALDX, $ALXO, $BBIO, $CGEN, $FULC, $GANX, $IMRX, $TARA, $XNCR, ASCO Genitourinary Cancers Symposium, biopharmaceutical, clinical-research, fda, new drug application, Oppenheimer 36th Annual Healthcare Life Sciences Conference, pr-newswire, press-releases, Wells Fargo Executive Biotech Summit, World ADC London 2026 -
FDA Approves Groundbreaking All-Oral, Fixed-Duration Treatment for Previously Untreated CLL
NYSE: $ABBV A Significant Advance in Chronic Lymphocytic Leukemia Treatment The U.S. Food and Drug Administration (FDA) has granted approval for the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for adult patients newly diagnosed with chronic lymphocytic leukemia (CLL). This pivotal decision, supported by robust data from the Phase 3 AMPLIFY trial, introduces the first…
-
10x Genomics Scheduled to Present at 46th Annual TD Cowen Health Care Conference
NASDAQ: $TXG 10x Genomics, Inc., a prominent innovator in the fields of single cell and spatial biology, has confirmed its participation in a significant industry event next month. The company announced that key members of its management team are slated to present at the highly anticipated 46th Annual TD Cowen Health Care Conference. The scheduled…
-
Compugen Set to Present at Key Investor Conferences in Early 2026
NASDAQ: $CGEN Compugen Ltd., a clinical-stage company pioneering cancer immunotherapy through advanced AI/ML-powered computational drug target discovery, has announced its management team will be participating in two significant investor conferences in the coming months. These appearances offer an important opportunity for stakeholders to gain insight into the company’s progress across its differentiated pipeline. The first…
-
QuidelOrtho Announces Presentation at Prestigious Raymond James 47th Annual Institutional Investor Conference
NASDAQ: $QDEL QuidelOrtho Corporation, a recognized global leader in innovative in vitro diagnostics, has officially announced its participation in a significant industry event: the Raymond James 47th Annual Institutional Investor Conference. This presentation offers a valuable opportunity for investors, analysts, and industry stakeholders to gain direct insight into the company’s strategic direction, recent performance, and…
-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…
-
FDA Greenlights FILKRI™: Accord BioPharma Completes Comprehensive G-CSF Portfolio for Oncology Support
Accord BioPharma Secures FDA Approval for FILKRI™ (filgrastim-laha), Biosimilar to NEUPOGEN® Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., has announced a significant milestone: the U.S. Food and Drug Administration (FDA) has approved FILKRI™ (filgrastim-laha). This product is a biosimilar to the established reference product, NEUPOGEN® (filgrastim). The approval, announced on February 17,…
-
Bio-Techne’s Ella Platform Secures CE-IVD Mark, Revolutionizing European Immunoassay Testing
NASDAQ: $TECH Bio-Techne Corporation, a leading global supplier of life science tools, reagents, and diagnostic products, has announced a major milestone: the Ella benchtop immunoassay platform has officially achieved CE-IVD marking and is now available for purchase throughout the European Union. This crucial certification opens the door for European clinical laboratories to adopt Ella’s industry-leading…
-
SOPHiA GENETICS Expands U.S. Footprint with Agreements with Two Major Integrated Health Systems
NASDAQ: $SOPH SOPHiA GENETICS, a recognized leader in AI-driven precision medicine, has significantly augmented its presence in the United States through agreements with two substantial, integrated healthcare systems. This expansion marks a pivotal moment in bringing advanced genomic analysis to a wider patient population across key regions. These two newly integrated institutions represent some of…